NanoViricides: Big Things In a Small Package
During an interview with OneMedPlace, President and Chairman of NanoViricides (NNVC) Anil Diwan summed up the influenza treatment market in just a few words: It is like trying to hit a moving target.
Articles by OneMedPlace Team
Cyto Wave Technologies CEO: First Device to Detect Circulating Tumor Cells In Vivo
Cyto Wave Technologies’ iV3 device can detect circulating tumor cells in real time via laser technology and potentially destroy cells. OneMedRadio spoke with Cyto Wave Technologies President and CEO George Yu about the favorable on-ramp to commercialization, clearing regulatory and reimbursement obstacles and the vast opportunity for in vivo CTC detection.
RELEASE: Mercator MedSystems Raises Additional $6.5 Million
Mercator MedSystems, Inc., a privately-held medical technology company reinventing the treatment of disease deep inside the body, today announced the closing of a $6.5 million Series B financing. The funding will be used to initiate sales of its Cricket™ and Bullfrog® Micro-Infusion devices in Europe, the United States and Australia.
The Healthcare Investor, July 17
Greetings from the OneMedPlace editorial desk. This is our first edition of The Healthcare Investor, a newsletter which captures the most interesting healthcare articles from […]
The 10 “Do’s and Don’t’s” When Networking at a Healthcare Conference
With OneMedForumNY 2013 just one month away (and a few healthcare conferences coming up), we thought it best to step away from our usual editorial functions and instead offer a ‘how to’ on enhancing your conference experience. Below, find 10 (actually, 11) tips to maximizing your conference networking. We’ve scattered in some special tricks, as well.
Associated Press: Omeros Corporation — Award Winning Drug OMS824 Being Tested to Treat Huntington’s & Schizophrenia
Omeros Corporation (OMER) will soon begin two mid stage clinical trials on its drug OMS824 which has greatly increased its stock prices. The company is testing its drug as a treatment for Huntington’s disease toward the end of 2013 as well as trials involved the treatment of Schizophrenia.
Zacks: Peregrine Pharma – On the Verge of Releasing First Oncology Drug to Market
Peregrine Pharma (PPHM) recently announced that the US. Food and Drug Administration (FDA) has approved on the design for their Phase III registration trial for its oncology drug, Bavituximab.
Seeking Alpha: Cyclacel on the Verge of Becoming a Competitor for Big Pharma
Cyclacel Pharmaceuticals (CYCC) has been raising the eyebrows of many investors recently. This multi-marketed company has several potential medications in its pipeline, including: acute myeloid leukemia, Phase III; myelodysplastic syndrome, Phase II; solid tumors, Phase I.
Motley Fool: Oncolytics – Cancer Killing Virus enters Phase II Metastatic Melanoma Trial
A unique drug is on the right pathway to success, as Oncolytics Biotechnology (ONCY) is pushing Reolysin through the pipeline. David Williamson from Motley Fool reported that this cancer medication is based off a common virus, incidentally referred to as the new “Cancer-Killing Virus.”
Genomic Visions: Cempra – Oral and Intravenous Fluoroketolid to Improve Community Health
Cempra (CEMP) is a biotechnology company focused on creating a new antibiotic, which may be “the next generation oral and intravenous fluoroketolid.” The company’s main antibiotic, Solithromycin, is currently in a Phase III study for community acquired bacterial pneumonia, as well as a mid-stage trial for gonorrhea.